Three biotechs hunt $336M-plus in a new round of IPOs — while Der­ma­vant pulls back

Raise mon­ey when you can, not when you must — the com­mon re­frain rang loud in two IPO fil­ings late Fri­day as ADC Ther­a­peu­tics and Fre­quen­cy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.